Amicus Therapeutics FOLD 2025Q2 Earnings Preview Upside Potential with Strong Patient Demand Projection

Forward-Looking Analysis
Amicus Therapeutics has set a revenue forecast for Q2 2025 of $147.63 million, backed by substantial patient demand for its key products, Galafold and Pombiliti + Opfolda. The company has adjusted its 2025 total revenue growth guidance to 15-22% at constant exchange rates. Despite a larger-than-expected loss in Q1, Amicus anticipates accelerating sales for Pombiliti + Opfolda in the second half of the year, with guidance revised to 50-65% growth. Analysts expect Amicus to achieve GAAP profitability during H2 2025, with a net income positive outlook driven by strategic in-licensing of Dimerix' DMX-200, expanding their portfolio in treating rare diseases. Amicus’ efforts to leverage its rare disease commercial infrastructure are projected to create substantial value for shareholders, positioning the company towards surpassing $1 billion in total sales by 2028. While previously expected revenue growth has been slightly tempered, the continuation of strong demand and strategic initiatives suggest promising performance for the remainder of the year.

Historical Performance Review
In Q1 2025, Amicus Therapeutics reported revenue of $125.25 million, marking a 15% year-over-year increase. Despite this revenue growth, the company faced a net loss of $21.69 million and an EPS of -$0.07. Gross profit stood at $113.55 million. While the company missed earnings expectations, the underlying demand for its products remains strong, suggesting potential for recovery in subsequent quarters.

Additional News
Amicus Therapeutics expanded its portfolio by in-licensing the Phase 3 program DMX-200 from Dimerix, aimed at treating the rare kidney disease FSGS, with significant market potential in the U.S. The company also secured regulatory approvals for Pombiliti + Opfolda in Canada and Australia. A five-year agreement in the Netherlands has positioned Pombiliti + Opfolda as the preferred treatment for late-onset Pompe disease. Additionally, Amicus reached a manufacturing agreement with Sharp Sterile to diversify its supply chain for Pombiliti. These strategic developments underscore the company's focus on expanding its product offerings and market presence.

Summary & Outlook
Amicus Therapeutics is positioned for growth with strategic initiatives and a robust product pipeline. The company’s financial health is bolstered by revenue forecasts and expanding product approvals. While past earnings show a net loss and missed projections, the underlying demand and strategic partnerships present a bullish outlook. The in-licensing of DMX-200 and regulatory approvals are key growth catalysts, potentially driving revenue beyond $1 billion by 2028. However, the adjusted revenue growth guidance and past earnings shortfall suggest cautious optimism, with expectations for profitability in the latter half of 2025.